|September 2000 (Volume 7, Issue 9)
Article 185: CROs Hand Poor Grades to Sponsors
Article 186: A Bitter Pill for SMOs
- Despite a growing need for sponsors to outsource their clinical projects, pharmaceutical companies are failing to manage effective relationships with CROs.
- A variety of practices, including preferred provider agreements, the RFP process, project team management approaches and the setting of project timelines, are largely facilitating adversarial, unproductive and inefficient collaborations.
Article 187: CentreStage Europe: Early Signs of a Market Shifting Toward For-Profit European Investigators
- The acquisition market for independent sites has dried up. Although select SMOs are looking to aggressively expand, this expansion will likely come from consolidation of existing and established site management networks.
- Sites acquired by SMOs have had mixed experiences -- particularly the largest and most experienced ones. This suggests yet another challenge SMOs face as they strive to build primary demand for their services.
Article 188: Eye On: Colorectal Cancer
- According to Pharmaprojects, as many as 10,000 projects will be in the worldwide pharmaceutical R&D pipeline within three years. This represents a 50% increase over the number of projects in discovery through clinical development today. This increase will drive the need for more patients, for more investigators and for much higher levels of development spending.
- Colorectal cancer or colon cancer is the second most common cause of cancer death today. It is the third most common cancer in men and the second most common cancer found in women. CenterWatch has identified 34 drugs in phase I-III development for colorectal cancer. Approximately $183.8 million is spent annually to study the effects of these treatments on colorectal cancer.